These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
470 related articles for article (PubMed ID: 21520036)
1. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome. Tresallet C; Brouquet A; Julié C; Beauchet A; Vallot C; Ménégaux F; Mitry E; Radvanyi F; Malafosse R; Rougier P; Nordlinger B; Laurent-Puig P; Boileau C; Emile JF; Muti C; Penna C; Hofmann-Radvanyi H Int J Cancer; 2012 Mar; 130(6):1367-77. PubMed ID: 21520036 [TBL] [Abstract][Full Text] [Related]
2. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491 [TBL] [Abstract][Full Text] [Related]
3. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055 [TBL] [Abstract][Full Text] [Related]
4. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers. Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164 [TBL] [Abstract][Full Text] [Related]
5. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines. Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M Tumori; 2014; 100(3):315-20. PubMed ID: 25076244 [TBL] [Abstract][Full Text] [Related]
6. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526 [TBL] [Abstract][Full Text] [Related]
7. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Bessa X; Ballesté B; Andreu M; Castells A; Bellosillo B; Balaguer F; Castellví-Bel S; Paya A; Jover R; Alenda C; Titó L; Martinez-Villacampa M; Vilella A; Xicola RM; Pons E; Llor X; Clin Gastroenterol Hepatol; 2008 Feb; 6(2):206-14. PubMed ID: 18096441 [TBL] [Abstract][Full Text] [Related]
8. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Clendenning M; Sotamaa K; Prior T; Westman JA; Panescu J; Fix D; Lockman J; LaJeunesse J; Comeras I; de la Chapelle A J Clin Oncol; 2008 Dec; 26(35):5783-8. PubMed ID: 18809606 [TBL] [Abstract][Full Text] [Related]
9. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability. Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639 [TBL] [Abstract][Full Text] [Related]
10. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358 [TBL] [Abstract][Full Text] [Related]
13. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. Parsons MT; Buchanan DD; Thompson B; Young JP; Spurdle AB J Med Genet; 2012 Mar; 49(3):151-7. PubMed ID: 22368298 [TBL] [Abstract][Full Text] [Related]
14. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome. van Lier MG; Leenen CH; Wagner A; Ramsoekh D; Dubbink HJ; van den Ouweland AM; Westenend PJ; de Graaf EJ; Wolters LM; Vrijland WW; Kuipers EJ; van Leerdam ME; Steyerberg EW; Dinjens WN; J Pathol; 2012 Apr; 226(5):764-74. PubMed ID: 22081473 [TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842 [TBL] [Abstract][Full Text] [Related]
16. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306 [TBL] [Abstract][Full Text] [Related]
17. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents. Bodo S; Colas C; Buhard O; Collura A; Tinat J; Lavoine N; Guilloux A; Chalastanis A; Lafitte P; Coulet F; Buisine MP; Ilencikova D; Ruiz-Ponte C; Kinzel M; Grandjouan S; Brems H; Lejeune S; Blanché H; Wang Q; Caron O; Cabaret O; Svrcek M; Vidaud D; Parfait B; Verloes A; Knappe UJ; Soubrier F; Mortemousque I; Leis A; Auclair-Perrossier J; Frébourg T; Fléjou JF; Entz-Werle N; Leclerc J; Malka D; Cohen-Haguenauer O; Goldberg Y; Gerdes AM; Fedhila F; Mathieu-Dramard M; Hamelin R; Wafaa B; Gauthier-Villars M; Bourdeaut F; Sheridan E; Vasen H; Brugières L; Wimmer K; Muleris M; Duval A; Gastroenterology; 2015 Oct; 149(4):1017-29.e3. PubMed ID: 26116798 [TBL] [Abstract][Full Text] [Related]
18. Validation microsatellite path score in a population-based cohort of patients with colorectal cancer. Bessa X; Alenda C; Paya A; Álvarez C; Iglesias M; Seoane A; Dedeu JM; Abulí A; Ilzarbe L; Navarro G; Pellise M; Balaguer F; Castellvi-Bel S; Llor X; Castells A; Jover R; Andreu M J Clin Oncol; 2011 Sep; 29(25):3374-80. PubMed ID: 21788563 [TBL] [Abstract][Full Text] [Related]
19. Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach. Hartman DJ; Brand RE; Hu H; Bahary N; Dudley B; Chiosea SI; Nikiforova MN; Pai RK Hum Pathol; 2013 Nov; 44(11):2518-28. PubMed ID: 24034859 [TBL] [Abstract][Full Text] [Related]
20. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]